Prodrug therapy is one strategy to deliver anticancer drugs in a less reactive manner to reduce nonspecific cytotoxicity. A new multifunctional anticancer
prodrug system based on water-dispersible
fullerene (C60) aggregates is introduced; this
prodrug system demonstrates active targeting, pH-responsive
chemotherapy, and photodynamic therapeutic (
PDT) properties. Incorporating (via a cleavable bond) an anticancer
drug, which is
doxorubicin (DOX) in this study, and a targeting
ligand (
folic acid) onto
fullerene while maintaining an overall size of approximately 135 nm produces a more specific anticancer
prodrug. This
prodrug can enter
folate receptor (FR)-positive
cancer cells and kill the cells via intracellular release of the active
drug form. Moreover, the
fullerene aggregate carrier exhibits
PDT action; the cytotoxicity of the system towards FR-positive
cancer cells is increased in response to light irradiation. As the DOX
drug molecules are conjugated onto
fullerene, the DOX fluorescence is significantly quenched by the strong electron-accepting capability of
fullerene. The fluorescence restores upon release from
fullerene, so this fluorescence quenching-restoring feature can be used to track intracellular DOX release. The combined effect of
chemotherapy and
PDT increases the therapeutic efficacy of the DOX-
fullerene aggregate
prodrug. This study provides useful insights into designing and improving the applicability of
fullerene for other targeted
cancer prodrug systems.